ARTICLE SUMMARY:
Most venture capital firms like to mitigate risk by having a diversified portfolio, taking an opportunistic approach to clinical and technology spaces. But Innogest, one of the most active medtech investors around today, is betting on a strategy focused on cardiovascular, with an incubator to supplement its efforts.
Though they may have certain preferences or biases, often born out of past successes, most venture capital firms like to diversify their portfolios, both within medical devices— with investments in cardiovascular, orthopedics, and other clinical areas—and across segments, investing in biotech, medical devices, and, increasingly, digital health.
